Nephros, Inc. (Nephros) is engaged primarily in the development of hemodiafiltration (HDF), products and technologies for treating patients with end stage renal disease (ESRD). The Company has three products in various stages of development in the HDF modality to deliver therapy to ESRD patients: OLpur MDHDF filter series (which it sells in various countries in Europe and consists of its MD190 and MD220 diafilters); for HDF therapy and employing its Mid-Dilution Diafiltration technology; OLpur H2H, the Company’s add-on module designed to allow the most common types of hemodialysis machines to be used for HDF therapy, and OLpur NS2000 system, its stand-alone HDF machine and associated filter technology. Nephros has also developed its OLpur HD 190 high-flux dialyzer cartridge, which incorporates the same materials as its OLpur MD series but does not employ its Mid-Dilution Diafiltration technology.